Kyruus and Hyro Form Partnership to Help Healthcare Organizations Boost Online Conversion Through Digital Self-Service
Partnership will Enable Healthcare Organizations to Enhance Conversational AI Experiences with Robust Provider Search and…
News
Kalao integrates Ramp to drive the mainstream adoption of NFTs
London, UK: 14 April 2022 – Payments infrastructure provider Ramp has partnered with Kalao, a…
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference
April events to highlight Longeveron’s commitment to developing cell therapeutics for chronic aging related diseases….
Junshi Biosciences and Coherus Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
SHANGHAI, China and REDWOOD CITY, Calif., April 14, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences…
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly…
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share…
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
 Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well…
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”,…
Vaxart to Present at World Vaccine Congress Washington 2022Â on April 20
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today…
Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022
MARLBOROUGH, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
BOSTON, April 14, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
AGTC to Present at Cell & Gene Meeting on the Mediterranean
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, California Cell Forge…
22nd Century Group (Nasdaq: XXII) to Announce First Quarter 2022 Results on May 5, 2022
BUFFALO, N.Y., April 14, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference
BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James…
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc….
Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com
LOS ANGELES, April 14, 2022 (GLOBE NEWSWIRE) — Sera Labs, a wholly subsidiary of CURE…
Reflect Scientific’s Cryometrix Brand Solvent Chillers Off to a Hot Start
OREM, Utah, April 14, 2022 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider…
Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with…
Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
29% increase in Twirla cycles27% increase in total prescriptions (TRx) of Twirla PRINCETON, N.J., April…